Tvardi Therapeutics
TVRD
173 hedge funds and large institutions have $444M invested in Tvardi Therapeutics in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 49 reducing their positions, and 36 closing their positions.
14% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 36
3% more funds holding
Funds holding: 168 → 173 (+5)
8% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 49
7% more call options, than puts
Call options by funds: $5.8M | Put options by funds: $5.45M
0.08% less ownership
Funds ownership: 1.8% → 1.73% (-0.08%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $703M → $444M (-$259M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$63.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.66M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$47.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$22M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
-$19.5M |
| 4 |
RCP
Rho Capital Partners
New York
|
-$18.5M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$9.32M |
TVRD Hedge Fund Activity: Q2 2021 in Review
173 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2021, worth a combined $444M — down 37% from $703M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new TVRD positions and 36 closed out — a net gain of 5 holders — while 53 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock, adding an estimated $63.5M. The largest seller was First Manhattan, exiting entirely with an estimated $47.1M sold.
- 173 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2021, up from 168 in Q1 2021.
- Funds reported $444M of Tvardi Therapeutics stock for Q2 2021, down 37% quarter-over-quarter.
- 41 funds opened new Tvardi Therapeutics positions in Q2 2021 and 36 closed out, a net change of +5 holders.
- The largest Tvardi Therapeutics buyer in Q2 2021 was BlackRock, an estimated $63.5M added.
- The largest Tvardi Therapeutics seller in Q2 2021 was First Manhattan, an estimated $47.1M sold.
Based on aggregated 13F filings for Q2 2021.